Related Experiment Video
Updated: May 7, 2026
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Emerging BRAF inhibitors for melanoma
Francesco Sabbatino1, Yangyang Wang, Xinhui Wang
1Massachusetts General Hospital, Harvard Medical School, Department of Surgery , 55 Fruit Street, Boston, MA 02114 , USA +1 617 726 6087 ; sferrone@partners.org.
Expert Opinion on Emerging Drugs
|October 1, 2013
Summary
BRAF inhibitor therapy shows promise for metastatic melanoma but faces resistance. New combinatorial strategies are needed to overcome resistance and improve patient outcomes in BRAF-mutant melanoma.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- BRAF inhibitor (BRAF-I) therapy is a breakthrough for metastatic melanoma with BRAF mutations.
- Therapeutic efficacy is limited by intrinsic and acquired drug resistance.
Purpose of the Study:
- Review the role of wild-type and mutated BRAF in melanoma.
- Discuss BRAF-I efficacy, resistance mechanisms, and combinatorial strategies.
- Identify key questions for optimizing BRAF-I therapy.
Main Methods:
- Literature review of BRAF inhibitor therapy in melanoma.
- Analysis of BRAF mutation roles and resistance mechanisms.
- Discussion of current and future combinatorial treatment strategies.
Main Results:
- BRAF mutations drive melanoma tumorigenesis and BRAF-I is a breakthrough treatment.
- Drug resistance is a significant challenge, necessitating advanced therapeutic approaches.
- Combinatorial strategies targeting multiple pathways improve efficacy but novel mechanisms are required.
Conclusions:
- BRAF inhibitors offer a major advance in metastatic melanoma treatment.
- Drug resistance necessitates individualized combinatorial treatments to overcome escape mechanisms.
- Novel strategies beyond targeting signaling pathways are needed for improved outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...